HU308, A Selective Cannabinoid Type-2 Receptor Agonist, Mitigates SARS-CoV-2 Spike Protein–Induced Acute Lung Injury in Mice
Lung · 2026
DOI: 10.1007/s00408-026-00870-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung, 2026. Verfasst von Janette Lockett und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School at Old Dominion Uni…. Hauptthemen laut MEDLINE: Acute Lung Injury, Receptor, Cannabinoid, CB2, Spike Glycoprotein, Coronavirus, Cannabinoids. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ryan Translational Research Fund, Eastern Virginia Medical School..
Abstract (Originalsprache)
Introduction
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to pose major health challenges despite effective vaccination efforts. The sustained occurrence of breakthrough infections and emerging variants of the virus highlights the need for additional therapeutic strategies. Given the anti-inflammatory role of the cannabinoid type 2 receptor (CB2R), we examined the effect of CB2R activation in SARS-CoV-2 spike protein subunit 1 (S1SP)-induced acute lung injury (ALI).
Methods
ALI was induced in mice by intratracheal (i.t.) administration of S1SP, followed by treatment with the CB2R agonist HU308 (5 mg/kg, intraperitoneal: i.p.) 1 h post-S1SP and every 24 h thereafter. Lung function, bronchoalveolar lavage fluid (BALF) parameters, cytokine levels, and inflammatory signaling were assessed at 48 h following S1SP exposure.
Results
HU308 treatment significantly reduced S1SP-induced pulmonary dysfunction, immune cell infiltration, neutrophil activation, and proinflammatory cytokine production, while suppressing NF-κB and STAT3 activation. HU308 treatment restored the Nrf2 expression in the lung.
Conclusion
CB2R activation ameliorates S1SP-induced lung inflammation and injury, suggesting its therapeutic potential against COVID-19-related ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School at Old Dominion University, Norfolk, VA, 23507, USA.
- Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School at Old Dominion University, Norfolk, VA, 23507, USA. nagren@odu.edu.
Förderung
- Ryan Translational Research Fund, Eastern Virginia Medical School.
Zitieren
APA
Lockett, J., Nicholson, G., Richards, N., Washington, R., & Nagre, N. (2026). HU308, A Selective Cannabinoid Type-2 Receptor Agonist, Mitigates SARS-CoV-2 Spike Protein–Induced Acute Lung Injury in Mice. Lung. https://doi.org/10.1007/s00408-026-00870-6
Vancouver
Lockett J, Nicholson G, Richards N, Washington R, Nagre N. HU308, A Selective Cannabinoid Type-2 Receptor Agonist, Mitigates SARS-CoV-2 Spike Protein–Induced Acute Lung Injury in Mice. Lung. 2026. doi:10.1007/s00408-026-00870-6
BibTeX
@article{Lockett2026,
author = {Lockett, Janette and Nicholson, Gregory and Richards, Nicholas and Washington, Ryan and Nagre, Nagaraja},
title = {HU308, A Selective Cannabinoid Type-2 Receptor Agonist, Mitigates SARS-CoV-2 Spike Protein–Induced Acute Lung Injury in Mice},
journal = {Lung},
year = {2026},
doi = {10.1007/s00408-026-00870-6}
}
EUVIMED